Skip to content
sellWeak10b5-1 plan

James Kihara sold $298k of ACAD

PRINCIPAL ACCOUNTING OFFICER at ACADIA PHARMACEUTICALS INC. 11,421 shares at an average of $26.08, traded Jun 26, 2026, filed Jun 29, 2026.

Warning score
19
Value
$298k
11,421 shares
Holdings after
13,088
-47% from before
From 52-week low
+26%
low $20.06, close $25.32
From 52-week high
-10%
high $28.06, as of Jun 26, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $298k at market
    +14
  • Share of holdings sold
    Sold 47% of holdings
    +10
  • Cluster
    No other insider selling within 14 days
    0
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ACADOct 9, 2026 · close 19.78
Since filing Jun 29, 2026: -21.5%SPY +5.3% · excess -26.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001816160-26-000009, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 26, 2026SOpen-market sale
Common Stock10b5-1
-11,421$26.08$298k13,088Jun 29, 2026

Related signals

Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
24Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$587k
20,141 shares
-27%
15Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Elizabeth H.Z. Thompson
EVP, Head of Research & Dev
$433k
16,558 shares
-47%
30Weak
ACADsell
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$114k
5,401 shares
-18%
0Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$29k
1,332 shares
-4%
3Weak
ACADsell 210b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$76k
3,506 shares
-5%
0Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$23k
1,030 shares
-4%
9Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Mark C. Schneyer
EVP, CHIEF FINANCIAL OFFICER
$60k
2,709 shares
-4%
14Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Jennifer J Rhodes
EVP, CHIEF LEGAL OFFICER, SEC
$83k
3,844 shares
-25%
1Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
James Kihara
PRINCIPAL ACCOUNTING OFFICER
$42k
1,942 shares
-7%
28Weak
ACADsell 510b5-1
ACADIA PHARMACEUTICALS INC
Adams Catherine Owen
Chief Executive Officer
$250k
11,641 shares
-44%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

James Kihara sold $298k of ACAD | InsiderTell